A kind of protohematoxylin B-3-O-β-D-glucoside and its preparation method and application
By extracting and isolating prohematoxylin B-3-O-β-D-glucoside from Yunshen, the problem of insufficient research on the chemical composition of Yunshen was solved, and significant anti-inflammatory effects were achieved, demonstrating its anti-inflammatory effect. Potential in inflammatory drugs.
Patent Information
- Application Number
- CN202211107459.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-09-13
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2042-09-13
AI Technical Summary
The prior art has not fully studied the chemical components contained in Yunshi peel, especially specific compounds with anti-inflammatory activity, and it is difficult to effectively utilize their medicinal effects.
A new compound prohematoxylin B-3-O-β-D-glucoside was extracted and isolated from Yunshi peel, and prepared by ethanol extraction, macroporous adsorption resin separation and high-pressure chromatography purification, and applied to anti-epidemic anti-epidemic chromatography. Inflammation drugs.
Prohematoxylin B-3-O-β-D-glucoside significantly downregulates the secretion of TNF-α, IL-1β, and IL-6, showing good anti-inflammatory effects, close to the effect of the positive drug dexamethasone.
Smart Images

Figure CN115260258B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medical technology, and specifically relates to protohematoxylin B-3-O-β-D-glucoside and a preparation method and application thereof. Background Art
[0002] Caesalpinia decapetala (Roxb.) Alston is a dried root or root bark of the leguminous plant Caesalpinia decapetala (Roxb.) Alston. It has the effects of dispelling wind and dampness, detoxifying and reducing swelling, and is often used to treat colds, fever, coughs, rheumatism and pain. Caesalpinia decapetala mainly contains coumarins, flavonoids and terpenes, and has good anti-inflammatory, antiviral and anti-malarial activities. For example, catechins, sappanone chalcone and protosappanin B (PTB) can downregulate the secretion of TNF-α and IL-6, thereby exerting an anti-inflammatory effect. Further research is needed on the chemical components contained in Caesalpinia decapetala. Summary of the invention
[0003] In view of the above problems, the purpose of the present invention is to provide a new compound protohematoxylin B-3-O-β-D-glucoside extracted and separated from the bark of Caesalpinia scoparia.
[0004] To achieve the above purpose, the technical solution adopted by the present invention is:
[0005] A protohematoxylin B-3-O-β-D-glucoside, the structural formula of the protohematoxylin B-3-O-β-D-glucoside is as follows:
[0006]
[0007] A method for preparing the protohematoxylin B-3-O-β-D-glucoside comprises the following steps:
[0008] (1) ethanol extraction: Take the skin of Caesalpinia scoparia and add ethanol to extract to obtain an extract;
[0009] (2) separation with macroporous adsorption resin; the extract is concentrated, loaded onto D101-8 macroporous adsorption resin, eluted with water, 50% ethanol and 90% ethanol in sequence, the 50% ethanol eluate is collected, concentrated, repeatedly loaded onto D101-8 macroporous resin, eluted with water, 50% ethanol and 20% ethanol in sequence, the 50% ethanol eluate is collected, concentrated, and a concentrated solution is obtained;
[0010] (3) Purification: The concentrated solution was loaded onto a medium pressure purification system, and gradient eluted with water, 5% acetonitrile, 10% acetonitrile, 25% acetonitrile, 35% acetonitrile, 50% acetonitrile and 90% acetonitrile in sequence, and the 25% acetonitrile eluate was collected, concentrated, and dissolved in 50% methanol aqueous solution, and high pressure preparation was performed using Welch UItimate XB-C 18 Chromatographic column, eluted with 7% acetonitrile aqueous solution, after collecting the target fraction, condensed the organic solvent at 50°C and then freeze-dried to obtain the sample, which was then dissolved in pure water and prepared under high pressure for the second time, using a Kromasil C4 column chromatographic column, eluted with 9% acetonitrile aqueous solution, after collecting the target fraction, condensed the organic solvent at 50°C and then freeze-dried to obtain the product.
[0011] Preferably, the ethanol extraction in step (1) is performed by cold soaking, and the ethanol concentration of the ethanol extraction is 80% ethanol aqueous solution.
[0012] The present invention also provides an application of the protohematoxylin B-3-O-β-D-glucoside in the preparation of anti-inflammatory drugs.
[0013] Preferably, the inflammation is an inflammatory response caused by LPS.
[0014] The present invention also provides a pharmaceutical preparation, comprising a therapeutically effective amount of protosutoxylin B-3-O-β-D-glucoside as claimed in claim 1 and a pharmaceutically acceptable carrier or excipient, wherein the pharmaceutical preparation is an oral preparation or an injection preparation.
[0015] In the present invention, unless otherwise specified, % refers to volume percentage.
[0016] Beneficial effects of the present invention:
[0017] The protohematoxylin B-3-O-β-D-glucoside of the invention is extracted and separated from safflower wood, can significantly reduce the secretion of TNF-α, IL-1β and IL-6, and has an anti-inflammatory effect close to that of the positive drug dexamethasone, and has a good anti-inflammatory effect. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 For PTD 1 H-NMR spectrum;
[0019] Figure 2 For PTD 13 C-NMR spectrum;
[0020] Figure 3 is the HMBC spectrum of PTD (A);
[0021] Figure 4 is the HMQC spectrum of PTD (B);
[0022] Figure 5 It is the important HMBC correlation diagram of PTD;
[0023] Figure 6 is the toxic effect of PTD (A) on RAW264.7 cells;
[0024] Figure 7 is the toxic effect of PTB (B) on RAW264.7 cells;
[0025] Figure 8 The effects of PTD and PTB on LPS-induced secretion of TNF-α, IL-1β, IL-6 and NO in RAW264.7 cells;
[0026] Fig.9A UHPLC / Q Extractive Plus MS / MS mass spectrum of PTD (A);
[0027] Fig. 9B The simulated fragmentation law of PTD in negative ion mode (B);
[0028] Fig.10 The chromatograms of the positive ion mode before and after oral administration of PTD are shown;
[0029] Fig.11 Negative ion mode chromatograms before and after oral administration of PTD;
[0030] Fig.12 UPLC-MS / MS chromatograms of analytes and internal standards: A. blank plasma; B. blank plasma plus reference solution; C. plasma after 30 minutes of PTD administration;
[0031] Fig.13 is the Ct drug-time curve of PTD in rat plasma after oral administration of PTD (27.3 mg / kg) n=5);
[0032] Fig.14 is the Ct drug-time curve of PTB in rat plasma after oral administration of PTD (27.3 mg / kg) n=5);
[0033] Fig.15 The Ct drug-time curve of PTD in rat plasma after intravenous injection of PTD (9.1 mg / kg) n=5);
[0034] Fig.16 The Ct drug-time curve of PTB in rat plasma after intravenous injection of PTD (9.1 mg / kg) n=5);
[0035] Fig.17 It is the chemical structural formula of protohematoxylin B-3-O-β-D-glucoside. DETAILED DESCRIPTION
[0036] Example 1
[0037] A protohematoxylin B-3-O-β-D-glucoside, the structural formula of the protohematoxylin B-3-O-β-D-glucoside is as follows:
[0038]
[0039] This embodiment also provides a method for preparing protohematoxylin B-3-O-β-D-glucoside, comprising the following steps:
[0040] 15 kg of coarse powder of marble bark medicinal material was added with 8 times the amount of 80% ethanol for cold soaking extraction for 5 days, filtered, and the extract was concentrated to 20 L. It was separated with D101-8 macroporous resin, washed with 70 L of water, 20 L of 50% ethanol, and 30 L of 90% ethanol in sequence, and the 50% ethanol eluate was collected and concentrated to 2.5 L. The D101-8 macroporous resin was repeated, and 90 L of water, 25 L of 50% ethanol, and 15 L of 20% ethanol were washed in sequence. The 50% ethanol eluate was collected and concentrated to 250 mL. It was purified by medium pressure, and gradient elution was performed with water, 5% acetonitrile, 10% acetonitrile, 25% acetonitrile, 35% acetonitrile, 50% acetonitrile and 90% acetonitrile in sequence. The 25% acetonitrile eluate was collected and concentrated to a small volume, and 50% methanol water was added to dissolve it to 100 mL. High pressure preparation was performed using Welch UItimate XB-C 18 Chromatographic column (50×250mm, 10μm), eluted with 7% acetonitrile water, flow rate 70mL / min, collect the target fraction, concentrate the organic solvent at 50°C and freeze-dry to obtain 1.0g sample, dissolve it in 30mL pure water, prepare it under high pressure for the second time, use Kromasil C4 column chromatographic column (30×250mm, 5μm), eluted with 9% acetonitrile water, flow rate 40mL / min, collect the target fraction, concentrate the organic solvent at 50°C and freeze-dry to obtain protohematoxylin B-3-O-β-D-glucoside (PTD).
[0041] 1. Structural identification of PTD
[0042] PTD is a white solid. HR-QTOF-MS gives its quasi-molecular ion peak m / z 465.1385 [MH]- (calculated value is 465.1402). 1 H-NMR and 13 C-NMR spectrum confirmed that the molecular formula is C 22 H 26 O 11. Based on the data of mass spectrometry, HMBC spectrum, one-dimensional NMR and two-dimensional NMR, all the hydrocarbon signals of PTD were accurately assigned, and it was found that it was a mixture of two dibenzoyloxyoctyl glycosides. According to literature reports, it was basically consistent with the mixture of protosappanoside A and isoprotosappanoside A. After analysis, its chemical structure was determined to be protosappanoside B-3-O-β-D-glucoside, named protosappanoside D and isoprotosappanoside D.
[0043] 1.PTD 1 H-NMR spectrum
[0044] 1 H-NMR (600MHz, CD3OD) showed that there were two 1,2,4-trisubstituted benzene ring systems in the low field region: δ H 7.10,7.10 (1H,1H,d,J=8.5Hz,H-1),6.89,6.84 (1H,1H,d,J=8.5Hz,H-2),6.84,6.78 (1H,1H,d,J=2.5Hz,H-4); 2 1,2,4,5-tetrasubstituted benzene ring systems: δ H 6.74, 6.69 (1H, 1H, s, H-12), 6.75, 6.75 (1H, 1H, m, H-9); 2 sugar terminal proton signals δ H 4.96,4.94 (1H,1H,d,J=8.1,7.6Hz,Glc-1′), according to its coupling constant, it can be inferred that the glycosidic bond is β-configuration; 8 oxymethylene hydrogen signals δ H 4.42, 4.19 (1H, 1H, m, H-6b), 3.92, 3.58 (1H, 1H, d, J = 11.8, 12.3 Hz, H-6a), 3.56, 3.41 (1H, 1H, overlapped, C7-CHa), 3.56, 3.49 (1H, 1H, overlapped, C7-CHb); 2 groups of hydrogen signals coupled to the same carbon δ H 2.72, 2.67 (1H, 1H, d, J = 13.6 Hz, H-8CHb), 2.56, 2.52 (1H, 1H, d, J = 13.6 Hz, H-8CHa). Figure 1 .
[0045] 2.PTD 13 C-NMR spectrum
[0046] 13 The C-NMR (150 MHz, CD3OD) spectrum showed 44 carbon signals, including 2 pyranose glucose signals (δC 102.2,102.2,78.1,78.1,78.0,78.0,74.9,74.9,71.4,71.4,62.5,62.5); 6 methylene carbon signals (δ C 76.9, 76.8, 65.8, 68.4, 42.6, 40.0); 2 quaternary carbon signals (δ C 73.2,72.9); the remaining signals are carbon signals on the benzene ring (δ C See 160.4,159.5,159.3,159.3,145.2,145.2,145.1,145.1,132.8,132.1,132.1,131.6,128.3,127.9,127.6,127.0,120.1,119.1,117.9,117.6,113.1,112.6,110.6,110.0). Figure 2 .
[0047] 3. HMBC and HMQC spectra of PTD
[0048] H-1 is related to C-3, H-2 to C-4 / C-12b, H-4 to C-12b / C-3 / C-4a, H-6 to C-4a / C-7 / C-8, H-8 to C-6 / C-7 / C-7a / C-9 / C-8a / C-12a, H-9 to C-8 / C-11, H-12 to C-10 / C-8a / C-12b, and H-1′ to C-3, indicating that the glucose group is connected to C-3 (see Figure 3-5 ).
[0049] 4. Attribution of PTD hydrocarbon signals
[0050]
[0051]
[0052] Comprehensive mass spectrometry, HMBC spectrum, one-dimensional NMR and two-dimensional NMR data, all the carbon and hydrogen signals of PTD were accurately assigned. After retrieval, PTD was found to be a pair of new compounds, and its chemical structure was determined to be protosappanoside D-3-O-β-D-glucoside, named protosappanoside D and isoprotosappanoside D.
[0053] 2. Pharmacodynamics and in vitro pharmacodynamics studies of PTD
[0054] 1. Pharmacodynamics study
[0055] 1.1 Cell culture and safe concentration investigation
[0056] Mouse mononuclear macrophage RAW264.7 cells were purchased from ATCC Cell Bank, USA, and cultured in DMEM complete medium containing 1% antibiotics and 10% fetal bovine serum in an incubator at 37°C and 5% CO2.
[0057] The MTS method was used to investigate the safe concentration of each drug under test. Cells with stable growth status were selected for the experiment and 1×10 5 The cells were inoculated with a density of 100 μL / mL in a 96-well plate. After culturing for 24 hours, the old culture medium was discarded, and the cells were washed twice with PBS. 0-500 μmol / L PTD and 0-400 μmol / L PTB were added to the cells for 24 hours. The cytotoxicity was detected by MTS method.
[0058] 1.2 Determination of inflammatory factors and NO
[0059] RAW264.7 cells were cultured at 1×10 5 The cell suspension was inoculated on a 96-well plate at a density of 100 μL per well and incubated in an incubator for 24 h. DMEM solution was added to the blank group, 1 μg / ml LPS solution was added to the model group, and 200 μmol / L PTD, 200 μmol / L PTB, and 100 μg / mL Dex solution were added to the PTD, PTB, and positive drug groups, respectively, and incubated with 1 μg / mL LPS solution. 100 μL per well
[18] , acted on RAW264.7 cells for 24 h, and the cell supernatant was collected. The secretion of TNF-α, IL-1β and IL-6 was measured using enzyme-linked immunosorbent assay (ELISA), and the secretion of NO in the cell supernatant was measured using the Griess kit.
[0060] 2. Method Validation
[0061] 2.1 Exclusivity
[0062] Take 100 μL of blank rat plasma, except for not adding puerarin internal standard, and operate according to the method under "2.4.2 Plasma Sample Processing Method" to obtain chromatogram A; add a certain concentration of internal standard solution and reference substance solution to the blank plasma, and operate according to the method to obtain chromatogram B; take the plasma of the rat after administration, and operate according to the method to obtain chromatogram C.
[0063] 2.2 Standard curve and linear range
[0064] Accurately measure appropriate amounts of two reference stock solutions such as PTD, dilute them with methanol in a gradient to the required concentration, and obtain a mixed series of reference solutions. Store them in the lower layer of the refrigerator (-20°C) for later use. Take 100μL of rat blank plasma, add 100μL of a series of mixed reference solutions, and prepare them to a concentration equivalent to that of rat drug-containing plasma, and operate according to "2.4.2". Use the ratio of the peak area of the component to be tested to the corresponding puerarin internal standard as the ordinate and the concentration of each substance as the abscissa for linear regression. The linear equation calculated by the least squares method is the standard curve. The lowest limit of quantification (LLOQ) of the two components such as PTD is defined as S / N=10, and the lowest limit of detection (LLOD) is defined as S / N=3.
[0065] 2.3 Accuracy and precision
[0066] Prepare three QC samples of two-component rat plasma at low, medium and high concentrations respectively, and perform parallel operation according to item "2.4.2", with 5 parallel samples for each concentration, and inject samples continuously within the day. Measure the three different concentrations continuously for 3 days, and calculate the intra-day precision and inter-day precision respectively.
[0067] 2.4 Extraction recovery and matrix effect
[0068] Prepare three samples A, B, and C respectively, take 100 μL of rat blank plasma, prepare three QC samples of low, medium, and high concentrations respectively according to "2.4.3", make 5 copies of each concentration in parallel, and operate according to "2.4.2" (A sample); take another 100 μL of blank plasma, except that no mixed reference solution is added, the rest is operated according to "2.4.2", add the corresponding low, medium, and high concentrations of mixed reference solution and puerarin internal standard to the supernatant obtained after centrifugation, blow dry, and dissolve the residue with 150 μL of 50% methanol (B sample); take another low, medium, and high concentrations of mixed reference solution and puerarin internal standard, blow dry, and dissolve the residue with 150 μL of 50% methanol (C sample). The extraction recovery rate is calculated by the ratio of the chromatographic peak area obtained by sample B to the chromatographic peak area obtained by sample A, and the matrix effect is calculated by the ratio of the chromatographic peak area obtained by sample B to the chromatographic peak area obtained by sample C. The puerarin internal standard was also investigated.
[0069] 2.5 Sample stability
[0070] According to item "2.4.3", three concentrations of plasma QC samples of two components, namely, protohematoxylin B-10-O-β-D-glucoside, were prepared respectively. The stability of the samples was investigated under three environments: room temperature (about 20°C), refrigerated at 4°C for 24 hours, and repeated freeze-thaw three times.
[0071] 3. Animal research
[0072] SPF grade SD (Sprague-Dawley) rats, half male and half female, weighing 230±10g, were provided by Changsha Tianqin Biotechnology Co., Ltd. (License No.: SCXK(Xiang)2014-0010). Rearing conditions: The animal room was well-lit, well-ventilated with air conditioning, relative humidity of 50±10%, room temperature of 22±2℃, and the laboratory was disinfected regularly. The rats were fed with ordinary pelleted rat feed, kept in separate cages, and had free access to water.
[0073] Metabolite study: Healthy SD rats were randomly divided into a treatment group and a blank group, with 6 rats in each group. The treatment group was gavaged with PTD 27.3 mg / kg for 3 consecutive days, twice a day. Blood was collected from the femoral artery 2 hours after the last administration, centrifuged at 6000 rpm for 6 minutes at 4°C, and 100 μL of plasma was separated and frozen at -20°C until analysis.
[0074] Pharmacokinetics experiment: Healthy SD rats were randomly divided into two groups, 6 in each group. The oral gavage group: the dosage was 27.3 mg / kg, the intravenous injection group: the dosage was 9.1 mg / kg, and 0.3 mL of blood was collected from the tail vein at 0.083, 0.167, 0.33, 0.5, 0.75, 1, 1.5, 2, 4, 6, 9, 12 and 24 h after administration, and placed in a centrifuge tube with heparin. Centrifuge at 6000 rpm for 6 min at 4 ° C, separate 100 μL of plasma and freeze at -20 ° C until analysis.
[0075] 4. Data processing
[0076] Compound discoverer 3.2 was used for the analysis of PTD metabolites; WinNonlin was used for pharmacokinetic parameter analysis, and Graphpad 8.2 was used for plotting. Statistical analysis was performed using SPSS 22.0 software, and the experimental results were expressed as means ± SD. One-way analysis of variance was used for comparison between groups, and bioavailability (F) was calculated according to the equation reported by He et al.
[0077] 5. Effects of the test drugs on the activity of RAW264.7 cells
[0078] PTD and PTB acted on the cells for 24 hours respectively. Figure 6-7 As shown in the figure, PTD below 200 μmol / L and PTB below 300 μmol / L had no significant effect on the growth of RAW264.7 cells. In the following experiments, 200 μmol / L PTD and PTB will be used respectively.
[0079] 2. Effect of PTD on LPS-induced secretion of TNF-α, IL-1β, IL-6 and NO in RAW264.7 cells
[0080] The results are as follows Figure 8 As shown in the figure, compared with the blank group, under LPS stimulation, the secretion of TNF-α, IL-1β, IL-6 and NO in the model group increased significantly, and was statistically significant, proving that the inflammatory model was successfully established; compared with the model group, both PTD and PTB could significantly downregulate the secretion of TNF-α, IL-1β and IL-6, and the anti-inflammatory effects of the two drugs were close to that of the positive drug dexamethasone, proving that their anti-inflammatory effects were better.
[0081] 3. Metabolite Identification
[0082] 1. Mass spectrometry analysis of PTD
[0083] In order to identify metabolites, it is necessary to have a comprehensive understanding of the characteristic product ions and fragmentation pathways of the parent compound. In this study, chromatographic and mass spectrometric conditions were optimized using PTD.
[0084] In negative ion mode, the PTD reference (C 22 H 26 O 11 ), which produces a quasi-molecular ion peak of m / z 465.1402 [MH]-, t R 4.32min (see Fig.9A ), and obtain the high collision energy mass spectrum of PTD and a series of fragment ion peaks. R =4.32min, m / z 465.1402, M0 was identified as the PTD prototype. After PTD reacted to remove the glucoside, at m / z 303.0871 (C 16 H 16 O6 - ) ions were generated. After the loss of H2O and CH2O, a large amount of fragmentation occurred on the side chain radical and the eight-membered ring skeleton. The ion at m / z 285.0767 (C 16 H 13 O5 - , due to the loss of H2O) to form a double bond. The ion at m / z 303.0871 further loses a neutral fragment of CH2O, opening the octet ring, and at m / z 273.0768 (C 15 H 13 O5 - ) produced an ion at m / z 255.0660 (C 15 H 11 O4 - ) and loses a C2H3O molecule at m / z 243.0659 (C 14 H 11 O4 -) is generated at m / z 273.0768 (C 15 H 13 O5 - ) lost a neutral C2H2O fragment and the ion at m / z 231.0758 (C 13 H 11 O4 - ) and further lost an O atom, resulting in an ion at m / z 215.0704 (C 13 H 11 O3 - ) ions are generated at the position of the PTD fragment ions. The proposed fragmentation pathways for the generation of PTD fragment ions are as follows: Fig. 9B ), which can be well used for the screening and identification of PTD metabolites.
[0085] 2. Identification of PTD metabolites
[0086] Metabolites in rat plasma were identified and analyzed. All samples were subjected to full scan and ion scan in positive ion mode. Combined with the differences in the mass spectra of biological samples before and after administration, a total of four metabolites were identified. Table 2 summarizes the mass spectrometry data of the metabolites. The error range between the calculated mass and the measured mass is -3.4 to 3.1 ppm, indicating relative accuracy. By comparing the chromatograms of the control, blank plasma, rat administration plasma, and blank plasma subtracted ( Figure 10-11 ) and searched for relevant literature. It was found that the ion at m / z 303.0874 was PTB, and its response was very high. Studies have shown that PTB has anti-tumor and anti-inflammatory activities. Therefore, it is necessary to study the pharmacokinetics of PTD and its metabolite PTB.
[0087] Table 2 Mass spectrometry data of PTD (M0) and its metabolites (M1-M4)
[0088]
[0089]
[0090] 4. Pharmacokinetic Studies
[0091] 1. UPLC-MS / MS method validation
[0092] 1.1 Exclusivity
[0093] Under the selected chromatographic and mass spectrometric conditions, the chromatograms of blank plasma, blank plasma with PTD, PTB, IS, and drug-containing plasma samples after oral administration of PTD for 30 minutes are shown in Figure 2. Fig.12 The retention times of PTD, PTB and IS were 0.74, 1.46 and 1.42 minutes, respectively. The components were well separated and the endogenous substances in plasma did not interfere with the determination of each component.
[0094] 1.2 Standard curve and linear range
[0095] The standard curves, linear ranges, correlation coefficients, and LLOQs of PTD and PTB in rat plasma are shown in Table 3. The two components had a good linear relationship within the linear range, and the standard curve correlation coefficient (R 2 ) is between 0.9958 and 0.9998.
[0096] Table 3 Regression curve equations of PTD and other two components
[0097]
[0098] 1.3 Accuracy and precision
[0099] The intra-day and inter-day precision and accuracy results are shown in Table 4. The results show that the RSD of intra-day and inter-day measurements is less than 15%, and the accuracy range is about 86.06-109.38%. These results indicate that this method is accurate, reliable, and reproducible, and meets the requirements of biological sample analysis methods.
[0100] 1.4 Extraction recovery and matrix effect
[0101] The results of the matrix effect and extraction recovery of PTD and PTB are shown in Table 5. The extraction recovery of the two analytes ranged from 87.65 to 103.25%; the matrix effect ranged from 88.83 to 105.08%. The experimental results showed that the extraction recovery was good, there was no obvious matrix effect, and both met the requirements of the biological sample analysis method.
[0102] 1.5 Stability
[0103] The sample stability results are shown in Table 6. The results showed that the three plasma samples were relatively stable at room temperature for 24 h, refrigerated for 24 h, and after three freeze-thaw cycles, and the RSD of all samples under the above conditions were within 15%.
[0104] Table 4 Accuracy and precision of two analytes in rat plasma (n=5)
[0105]
[0106] Table 5 Extraction recovery and matrix effect of two analytes in rat plasma (n=5)
[0107]
[0108] Table 6 Stability of two analytes in rat plasma (n=5)
[0109]
[0110]
[0111] 3.4.2 Pharmacokinetic studies
[0112] The pharmacokinetics of PTD in rats were determined by the above method. The plasma concentration-time curve is shown in Figure 13-16 The pharmacokinetic parameters are shown in Table 7. PTD and its metabolite PTB can be detected by both oral and intravenous administration. After oral administration of PTD, rats reached a maximum plasma concentration of about 0.49h, and the t1 / 2z of oral and intravenous administration were 3.47±0.78h and 3.65±1.26h, respectively, while the MRT(0-t) were 3.06±0.63h and 2.07±0.57h, respectively, indicating that it has a fast absorption rate and a short residence time. Therefore, it can be quickly absorbed by the blood circulation and quickly excreted from the body. The AUC(0-t) after oral administration of PTD was 382.17±211.15ng / ml*h, and the AUC(0-t) after intravenous injection was 19364.32±10497.34ng / ml*h. The AUC(0-t) after intravenous injection of PTD was much greater than the AUC(0-t) after oral administration. Its bioavailability is about 0.65%. After oral administration, the AUC (0-t) of PTD was 382.17 ng / ml*h, and the AUC (0-t) of PTB was 179.33 ng / ml*h. The content of PTB in the body was about half of that of PTD.
[0113] Table 7 Pharmacokinetic parameters of PTD and PTB in rat plasma after oral administration of PTD (27.3 mg / kg) and intravenous injection of PTD (9.3 mg / kg) n=5)
[0114]
[0115] PTD is a compound first discovered in the extract of Caesalpinia calathea. Its chemical structure is very similar to that of PTB through nuclear magnetic resonance and mass spectrometry (see Figure 1 ), are all dibenzo-oxygenated eight-membered heterocyclic tricyclic nuclei. According to previous studies, PTB has good anti-inflammatory effects. [8] Therefore, it can be inferred that PTD may also have good anti-inflammatory activity. Therefore, this study used the most classic in vitro inflammatory model to detect the efficacy of PTD and PTB using LPS-induced RAW264.7 cells. [22-23] The experimental results showed that compared with the model group, both PTD and PTB could significantly downregulate the secretion of TNF-α, IL-1β, IL-6, etc. and exert anti-inflammatory effects, and the anti-inflammatory effect of PTB was similar to that reported previously. By comparing the anti-inflammatory activity of PTD and PTB, it was found that the two activities were similar. Therefore, PTD was further studied.
[0116] Since the parent nucleus structures of PTD and PTB are very similar, it is speculated that the two are prototypes or metabolites of each other. Previous studies have found that both PTB and PTD in the extract of Caesalpinia calamus can enter the blood. In order to eliminate the interference of PTB in the extract, this study administered PTD by oral and intravenous injection to explore the kinetic and transformation processes of PTD in vivo. In metabolic studies, it was found that the main metabolic pathways of PTD are desaturation, oxidation, methylation, alkylation, dehydration, degradation and desugaring, and the in vivo effectiveness of chemical components depends largely on their blood concentration and the activity of their metabolites. Therefore, it is of great significance to study the metabolites of PTD. The preliminary experiments compared the in vivo kinetic processes of these metabolites. The results showed that PTB is the main active metabolite of PTD, not only because of its high content, but also because only PTB has a relatively complete in vivo kinetic process. PTB is a compound obtained by its desugaring reaction, and there are related reports that PTB has anti-inflammatory and anticancer activities, which has great utilization value. Therefore, PTD has the potential to be used as a prodrug, and its value can be fully exerted through structural modification and transformation.
[0117] In order to further investigate the kinetics of PTD and its main metabolites in vivo, a UPLC-MS / MS method for the determination of PTD and PTB in biological samples was established for the first time in the pharmacokinetic experiment. The method is fast, simple, sensitive and stable. The positive and negative modes were scanned simultaneously, the scanning mode was selected ion monitoring (MRM), and the analysis time was 3 minutes, which greatly improved the experimental efficiency. The results of various methodological investigations in the experiment met the requirements of biological sample analysis and determination, and the operation was simple, the selectivity was good, and the sensitivity was high. The method was successfully used to study the pharmacokinetic process of PTD and PTB, and the relevant pharmacokinetic parameters were obtained. The experimental results showed that the Tmax, T1 / 2z and MRT (0-t) of PTD in rats after oral administration were 0.49h, 3.47h and 3.06h, respectively, indicating that it was absorbed quickly in the body and could be quickly absorbed into the blood circulation. At the same time, the residence time was short and it could be quickly converted into PTB and other metabolites. Bioavailability is a measure of the degree of absorption of drugs in the body. The higher the bioavailability of a drug, the better. The results showed that the AUC (0-t) of PTD after intravenous injection was significantly higher than that after oral administration, and its absolute bioavailability was low at only about 0.65%, indicating that the total amount of PTD entering the systemic circulation after oral administration was significantly reduced. It is speculated that some drugs are affected by the first-pass effect and are not absorbed, resulting in the low absolute bioavailability of PTD, but this does not mean that it is meaningless. If a drug has low bioavailability but high therapeutic exposure, it also has high development significance. We should adopt other methods to modify or transform it to fully utilize its value. Based on the formula: CL = kV, t1 / 2 =0.693 / k. However, t 1 / 2 The values of k and V after oral administration of PTD are close, indicating that the k after the two administrations are close, proving that CL is mainly affected by V. The CL and V after oral administration of PTD are much greater than those after intravenous injection. It is speculated that PTD is absorbed by the gastrointestinal tract after oral administration and is affected by gastrointestinal metabolic enzymes, making the V after oral administration much greater than that after intravenous injection, which leads to the CL after oral administration being much greater than that after intravenous injection. After oral administration, the AUC (0-t) of PTD is 382.17 ng / mL*h, and the AUC (0-t) of PTB is 179.33 ng / mL*h. The content of PTB in the body is about half of that of PTD, indicating that PTD is mainly converted into PTB, and the MRT (0-t) of PTB after both administration methods is significantly higher than that of PTD. It is speculated that the efficacy of PTD in the body may be attributed to the effects of PTB and other metabolites. This speculation needs further experiments to verify.
[0118] This experiment completed the structural identification, anti-inflammatory efficacy and in vivo pharmacokinetic process of PTD, which can be used as basic research before the clinical application of PTD, which is of great significance to the development and utilization of PTD.
[0119] PTD is a new compound isolated and extracted from the bark of Caesalpinia calamus for the first time. It was named protosedoxanthin B-3-O-β-D-glucoside after structural identification. In this study, it was found that PTD can play an anti-inflammatory role by downregulating the secretion of inflammatory factors such as TNF-α, IL-1β and IL-6, and its anti-inflammatory effect is close to that of PTB. In the metabolite study, a total of 4 metabolites were identified, and the main metabolic pathways were desaturation, oxidation, methylation, alkylation, dehydration, degradation and desugaring. Pharmacokinetic results showed that PTD can be rapidly absorbed and converted in the body, and its bioavailability is 0.65%. This article will report the structural identification, pharmacological activity, metabolite identification and pharmacokinetic study of PTD for the first time, which is of great significance for the development and utilization of PTD.
[0120] In this study, UHPLC / Q Exactive Plus MS technology combined with Compound Discoverer3.2 data analysis platform was used to rapidly analyze the metabolites of PTD in rat plasma, and data were collected in positive ion mode. Four metabolites were identified based on retention time, characteristic fragmentation patterns of PTD reference substances, precise molecular weight of metabolites, and characteristic fragment ions. The results showed that PTD mainly underwent alkylation, dehydration, desaturation, oxidation, methylation, degradation, and desugaring reactions in rats.
Claims
1. A method for preparing protohematoxylin B-3-O-β-D-glucoside, characterized in that: The structural formula of the protohematoxylin B-3-O-β-D-glucoside is as follows: The following steps are involved: (1) ethanol extraction: Take the skin of Caesalpinia scoparia and add ethanol to extract to obtain an extract; (2) separation with macroporous adsorption resin; the extract is concentrated, loaded onto D101-8 macroporous adsorption resin, eluted with water, 50% ethanol and 90% ethanol in sequence, the 50% ethanol eluate is collected, concentrated, repeatedly loaded onto D101-8 macroporous resin, eluted with water, 50% ethanol and 20% ethanol in sequence, the 50% ethanol eluate is collected, concentrated, and a concentrated solution is obtained; (3) Purification: The concentrated solution was loaded onto a medium pressure purification system, and gradient eluted with water, 5% acetonitrile, 10% acetonitrile, 25% acetonitrile, 35% acetonitrile, 50% acetonitrile and 90% acetonitrile in sequence, and the 25% acetonitrile eluate was collected, concentrated, and dissolved in 50% methanol aqueous solution, and high pressure preparation was performed using Welch UItimate XB-C 18 Chromatographic column, eluted with 7% acetonitrile aqueous solution, after collecting the target fraction, condensed the organic solvent at 50°C and then freeze-dried to obtain the sample, which was then dissolved in pure water and prepared under high pressure for the second time, using a Kromasil C4 column chromatographic column, eluted with 9% acetonitrile aqueous solution, after collecting the target fraction, condensed the organic solvent at 50°C and then freeze-dried to obtain the product.
2. The method for preparing protohematoxylin B-3-O-β-D-glucoside according to claim 1, characterized in that: The ethanol extraction in step (1) is performed by cold soaking, and the ethanol concentration of the ethanol extraction is 80% ethanol aqueous solution.
Citation Information
Patent Citations
Animal model construction method of mysorethorn bark drug pharmacokinetics and tissue distribution
CN114295753A
Dynamic inhibitors of heat shock protein 90
US20120309702A1
Compound for preventing and treating inflammation, and preparation method therefor and use thereof
WO2022160455A1
